详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Advances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Hematology and Institute of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, P. R. China. [2]The Experimental Animal Center of West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, P. R. China.

出处：

DOI：

ISSN：

关键词： acute myeloid leukemia drug resistance nanoparticle targeted drug delivery

摘要：

Acute myeloid leukemia (AML) is a common and catastrophic hematological neoplasm with high mortality rates. Conventional therapies, including chemotherapy, hematopoietic stem cell transplantation (HSCT), immune therapy, and targeted agents, have unsatisfactory outcomes for AML patients due to drug toxicity, off-target effects, drug resistance, drug side effects, and AML relapse and refractoriness. These intrinsic limitations of current treatments have promoted the development and application of nanomedicine for more effective and safer leukemia therapy. In this review, the classification of nanoparticles applied in AML therapy, including liposomes, polymersomes, micelles, dendrimers, and inorganic nanoparticles, is reviewed. In addition, various strategies for enhancing therapeutic targetability in nanomedicine, including the use of conjugating ligands, biomimetic-nanotechnology, and bone marrow targeting, which indicates the potential to reverse drug resistance, are discussed. The application of nanomedicine for assisting immunotherapy is also involved. Finally, the advantages and possible challenges of nanomedicine for the transition from the preclinical phase to the clinical phase are discussed.© 2024 Wiley‐VCH GmbH.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 2 区

材料科学

小类 | 1 区物理：应用 2 区化学：综合 2 区物理化学 2 区材料科学：综合 2 区纳米科技 2 区物理：凝聚态物理

第一作者：

第一作者机构： [1]Department of Hematology and Institute of Hematology, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, P. R. China.

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Glycolysis and chemoresistance in acute myeloid leukemia [2]Targeting PRAME for acute myeloid leukemia therapy [3]Dual tumor-targeted poly(lactic-co-glycolic acid)-polyethylene glycol-folic acid nanoparticles: a novel biodegradable nanocarrier for secure and efficient antitumor drug delivery [4]Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia. [5]Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia [6]Chimeric Antigen Receptor T Cells Targeting Cell Surface GRP78 to Eradicate Acute Myeloid Leukemia [7]Dual tumor-targeted poly(lactic-co-glycolic acid)–polyethylene glycol–folic acid nanoparticles: A novel biodegradable nanocarrier for secure and efficient antitumor drug delivery [8]Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia. [9]A novel bispecific T-cell engager using the ligand-target csGRP78 against acute myeloid leukemia [10]FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N-6-Methyladenosine RNA Demethylase